Agile Therapeutics to Present at the 2017 BIO CEO

PRINCETON, N.J., Feb. 02, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX ) a women’s health specialty pharmaceutical company, announced today that its Chief Executive Officer, Al Altomari will present at the 2017 BIO CEO & Investor Conference on Monday, February 13, 2017 at 11:00 am ET at the Waldorf Astoria in New York.

To access the live and archived webcasts of the presentation, visit the Investor Relations section of Agile Therapeutics website at www.agiletherapeutics.com .  The webcast will be archived on Agile Therapeutics website for 60 days following the event.

About Agile Therapeutics Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today's women. Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method.  Our lead product candidate, Twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch that recently completed Phase 3 trials. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability. For more information, please visit the company website at www.agiletherapeutics.com .

Contact:  Mary Coleman 609-683-1880